---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-004482"
form_type: "8-K"
ticker: "ALGS"
cik: "0001799448"
company_name: "Aligos Therapeutics, Inc."
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:27:13.503524+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aligos Q2 net income $5.1M on warrant revaluation; HERALD topline due early Q4

## Summary
- Cash $94.5M at June 30, down from $135.7M year-end; runway through end of 2025.
- Net income of $5.1M ($0.03/sh) vs net loss of $18.8M (-$0.43) YoY; non-cash warrant income $30.5M.
- R&D spend $21.1M (+26% YoY) on clinical trial costs; G&A $6.4M (-30% YoY).
- ALG-055009 (MASH) HERALD enrollment complete; topline data expected early Q4 2024.
- ALG-000184 (CHB) showed sustained HBV DNA suppression in 90-100% of subjects; FDA supports registration endpoint.

## SEC filing metadata
- accession: 0001171843-24-004482
- form_type: 8-K
- ticker: ALGS
- cik: 0001799448
- company_name: Aligos Therapeutics, Inc.
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799448/000117184324004482/0001171843-24-004482-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799448/000117184324004482/f8k_080624.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-004482
- JSON: https://secwatch.observer/filing/0001171843-24-004482.json
- Plain text: https://secwatch.observer/filing/0001171843-24-004482.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.